Literature DB >> 28825976

Polycystic ovary syndrome, personality, and depression: A twin study.

Carolyn E Cesta1, Ralf Kuja-Halkola2, Kelli Lehto3, Anastasia N Iliadou2, Mikael Landén4.   

Abstract

BACKGROUND: Women with polycystic ovary syndrome (PCOS) are at elevated risk for suffering from depression. Neuroticism is a personality trait that has been associated with an increased risk for developing major depressive disorder (MDD). The aim of the present study was to quantify and decompose the correlation between neuroticism, PCOS, and MDD into shared and unique genetic and environmental etiologies, by using quantitative genetic methods.
METHODS: In a cohort of 12,628 Swedish female twins born from 1959 to 1985, neuroticism, PCOS identified by symptoms of hyperandrogenemia (i.e., hirsutism) and oligo- and/or anovulation, and lifetime MDD status were determined through questionnaire responses. Structural equation modeling was used to study the genetic and environmental sources of the variation within, and covariation between neuroticism, PCOS, and MDD.
RESULTS: Female twins with PCOS (n=752) had significantly higher levels of neuroticism than women without PCOS, and a 2-fold increase in odds for a lifetime prevalence of MDD. The phenotypic correlation between PCOS and MDD was 0.19, with 63% of the correlation attributable to common genetic factors between the two traits. When taking into account neuroticism, 41% was attributable to common genetic factors and 9% attributable to common environmental factors shared between all three traits, with the remainder attributable to components unique to PCOS and MDD.
CONCLUSION: There are common genetic factors between neuroticism, PCOS, and MDD; however, neuroticism shares approximately half of the genetic and environmental components behind the phenotypic correlation between PCOS and MDD, providing some etiological evidence behind the comorbidity between PCOS and depression.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Depression; Neuroticism; Personality; Polycystic ovary syndrome; Twins

Mesh:

Year:  2017        PMID: 28825976     DOI: 10.1016/j.psyneuen.2017.08.007

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  6 in total

1.  Metformin Improves the Depression Symptoms of Women with Polycystic Ovary Syndrome in a Lifestyle Modification Program.

Authors:  Fatimah AlHussain; Yazed AlRuthia; Hazem Al-Mandeel; Arwa Bellahwal; Fadia Alharbi; Yasser Almogbel; Oriana Awwad; Roua Dala'een; Fawaz Abdullah Alharbi
Journal:  Patient Prefer Adherence       Date:  2020-04-15       Impact factor: 2.711

2.  Maternal polycystic ovary syndrome and risk of neuropsychiatric disorders in offspring: prenatal androgen exposure or genetic confounding?

Authors:  Carolyn E Cesta; Anna S Öberg; Abraham Ibrahimson; Ikram Yusuf; Henrik Larsson; Catarina Almqvist; Brian M D'Onofrio; Cynthia M Bulik; Lorena Fernández de la Cruz; David Mataix-Cols; Mikael Landén; Mina A Rosenqvist
Journal:  Psychol Med       Date:  2019-03-12       Impact factor: 7.723

3.  Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome.

Authors:  Rui Han; Xiaoyun Gong; Yuejie Zhu; Xiaoran Liu; Yan Xia; Yuhong Huang; Meng Zhang; Yunian Zhang; Xiaolin La; Jianbing Ding
Journal:  Biomed Res Int       Date:  2021-01-04       Impact factor: 3.411

4.  Paeoniflorin attenuates DHEA-induced polycystic ovary syndrome via inactivation of TGF-β1/Smads signaling pathway in vivo.

Authors:  Jie Zhou; Yong Tan; Xudong Wang; Meihong Zhu
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

Review 5.  Polycystic Ovary Syndrome, Affective Symptoms, and Neuroactive Steroids: a Focus on Allopregnanolone.

Authors:  Lindsay R Standeven; Elizabeth Olson; Nicole Leistikow; Jennifer L Payne; Lauren M Osborne; Liisa Hantsoo
Journal:  Curr Psychiatry Rep       Date:  2021-04-21       Impact factor: 5.285

6.  Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone).

Authors:  A Podfigurna; B Meczekalski; F Petraglia; S Luisi
Journal:  J Endocrinol Invest       Date:  2019-10-25       Impact factor: 5.467

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.